TG Therapeutics Inc. stocks have been trading up by 11.61 percent after upbeat trial results strengthened confidence in its pipeline.
Click Here for a Millionaire's POV on Trading TGTX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Need To Know
- TG Therapeutics raised its 2026 total revenue guidance to about $950M, powered by stronger BRIUMVI U.S. demand, positive Phase 3 data, and work on a subcutaneous version.
- Q2 2026 revenue of roughly $240M beat estimates and grew about 70% year over year, with U.S. BRIUMVI sales jumping 64% to $227.7M.
- EPS landed at $0.05 versus Street expectations in the $0.31–$0.44 range, and TGTX dropped 10.6% to $46.52 on the day despite bullish long‑term guidance.
- B. Riley lifted its TGTX price target to $86 from $55, while the Street’s average target sits near $64 with mostly Buy ratings.
- TG Therapeutics stayed profitable, finished Q2 with $612M in cash, and is pushing BRIUMVI into new indications like myasthenia gravis and schizophrenia.
Live Update At 12:32:10 EDT: On Friday, August 21, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 11.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TGTX is acting like a classic high‑growth biotech: noisy earnings, strong sales ramp, and aggressive guidance. For Q2 2026, TG Therapeutics printed about $240M in revenue, up roughly 70% year over year and ahead of consensus around $230M. Almost all of that came from BRIUMVI, with U.S. sales at $227.7M, up 64%. That tells traders the core product is gaining real share in multiple sclerosis.
On the bottom line, TGTX reported EPS of $0.05, well below the $0.31–$0.44 range the Street wanted. The miss reflects heavy spending on R&D and SG&A, including work on a subcutaneous BRIUMVI and pipeline expansion. Even so, TG Therapeutics stayed profitable, with about $7.8M in net income and EBITDA close to breakeven.
More Breaking News
- PMI Stock Slides As Losses Mount And Liquidity Tightens
- EOSE Stock Slides As Legal Probes And Losses Rattle Traders
- ACHR Stock Slips As Losses Mount And Insiders Signal Sales
- Beam Global Stock Jumps As Earnings Beat Fuels Growth Story
The balance sheet backs the story. TGTX ended the quarter with roughly $612M in cash and a current ratio near 4.3, giving the company room to keep funding trials without constant capital raises. Valuation is rich, with a P/E near 18.9 and price‑to‑sales about 9.9, but those numbers make sense only if traders believe the raised 2026 revenue guide to ~$950M and a $1B BRIUMVI U.S. run rate exiting 2026. That belief — or doubt — is what’s driving the tape.
Why Traders Are Locked In On TGTX
The tug‑of‑war in TGTX is clear on the chart and in the news. On 2026/08/03, TG Therapeutics delivered that mixed Q2 print: strong top line, weak EPS. Traders focused on margins first, and the stock slid 10.6%, dropping $5.51 to close at $46.52. That kind of one‑day flush in a liquid biotech name always gets momentum traders circling.
Under the hood, the fundamentals told a different story. Management raised 2026 total revenue guidance to about $950M, well above prior targets and Street consensus. They also boosted BRIUMVI U.S. guidance to the $890M–$905M range and talked about exiting 2026 at a roughly $1B annualized U.S. BRIUMVI run rate. For TGTX, that is a clear statement of conviction that current demand is not a one‑off spike.
Pipeline news adds fuel. TG Therapeutics reported positive Phase 3 ENHANCE data for a simplified single‑infusion IV initiation for BRIUMVI and is advancing a Phase 3 subcutaneous program. For traders, that means more convenience angles to defend and grow share. On top of MS, TGTX is pushing into myasthenia gravis and schizophrenia, expanding the potential revenue base beyond neurology’s core.
Wall Street is leaning into the growth story. B. Riley hiked its TGTX price target to $86 from $55 and kept a Buy rating. FactSet shows a mean target near $64 with mostly Buys. That tells active traders the sell‑side is willing to look past near‑term margin pressure as long as BRIUMVI keeps delivering and the broader TG Therapeutics franchise stays on track.
Technically, TGTX has snapped back hard from the post‑earnings flush. The daily data show the stock rebounding from the mid‑40s to close at $56.45 on 2026/08/21, after several sessions stair‑stepping from the high‑40s. Intraday, the 5‑minute tape shows a steady grind higher from the low‑50s at the open to mid‑56s by midday, with higher lows and contained pullbacks — classic accumulation behavior after a shakeout.
Conclusion
For active traders, TGTX is a live case study in how a strong fundamental story can clash with short‑term expectations. TG Therapeutics missed on Q2 EPS, paid for it with a sharp 10.6% drop, but then backed that up with raised 2026 revenue guidance, a powerful BRIUMVI ramp, and a $612M cash cushion. That combination — growth plus balance sheet strength — is not typical for commercial‑stage biotech, and it keeps TGTX on many watchlists.
The key trade‑off is simple. Bulls will focus on revenue growth near 70%, guidance moving toward $950M in 2026 sales, and a path to a $1B BRIUMVI U.S. run rate. Bears will point to rich valuation metrics, heavy R&D and SG&A, and execution risk as TG Therapeutics pushes into subcutaneous delivery and new diseases. The recent bounce toward the mid‑50s shows the market is willing to re‑rate the stock higher when selling pressure exhausts.
This is where discipline matters. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, it cares about your preparation — study the pattern, know the catalyst, and always be ready to cut losses fast.” As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” With TGTX, that means understanding the earnings catalyst, the raised guidance, and the tape action before you trade. This coverage is for educational and research purposes only and is not trading advice, but for chart‑driven traders, TG Therapeutics remains a name worth tracking every day.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.